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ABSTRACT:
Overexpression of Shc adaptor proteins is associated with mitogenesis, 
carcinogenesis and metastasis.  Multiple copies in T-cell malignancy 1 (MCT-1) 
oncoprotein promotes cell proliferation, survival and tumorigenic effects. Our current 
data show that MCT-1 is a novel regulator of Shc-Ras-MEK-ERK signaling and MCT-1 
is significantly co-activated with Shc gene in human carcinomas. The knockdown of 
MCT-1 enhances apoptotic cell death accompanied with the activation of caspases 
and cleavage of caspase substrates under environmental stress. The cancer cell 
proliferation, chemo-resistance and tumorigenic capacity are proved to be effectively 
suppressed by targeting MCT-1. Accordingly, an important linkage between MCT-
1 oncogenicity and Shc pathway in tumor development has now been established.  
Promoting MCT-1 expression by gene hyperactivation may be recognized as a tumor 
marker and MCT-1 may serve as a molecular target of cancer therapy.
INTRODUCTION
The development of cancer can be attributed to 
biological aberrations, including the ability to sustain 
proliferative signaling, to avoid growth suppressors, to 
resist cell death, to replicate indefinitely, to stimulate 
angiogenesis and chromosomal instability [1]. Src 
homolog and collagen homolog (Shc) (gene aliases, Shc 
1 and ShcA), the adaptor proteins transmit the signaling 
of cell surface receptors [2], such as EGF receptor 
(EGFR) [3], erbB-2 receptor [4] and insulin receptor 
[5].  Shc function was proved to be sufficient for tumor 
progression in MMTV/MT transgenic mice by knock-in 
alleles of the ShcA gene [6].  ShcA adaptor also plays a 
critical role in TGF-β- and Neu/ErbB-2-induced breast 
cancer cell motility and invasion [7]. The abundance of 
Shc protein is concomitant with human endometriosis 
which is associated with ERK1/2 hyperactivation and 
susceptibility to breast cancer [8].  Shc proteins have three 
isoforms with distinct molecular weights (46, 52 and 66 
kDa), playing multiple important roles in mitogenesis, 
carcinogenesis and metastasis [3, 9, 10].  For example, 
p52Shc and p46Shc activate Ras-ERK pathway [9, 12].  But, 
p66Shc was originally recognized as an inhibitor of ERK1/2 
activity and found to antagonize mitogenic and surviving 
abilities of T-lymphoma Jurkat cell line [13]. The increase 
in p66Shc promoted the stress-induced apoptosis and the 
p66Shc knockout mice were confirmed to have a longevity 
effect [11, 13, 14]. Moreover, p66Shc restrains Ras hyper-
activation, Rb-dependent proliferation and metastatic 
feature of lung carcinoma cells [15].
Paradoxically, p66Shc activates ERK1/2 and 
enhances proliferation of prostate cancer cells [16]. As 
well as, abundant expression of p66Shc was also recognized 
in many breast cancer cell lines and primary breast 
tumors with high metastatic potential [17], suggesting 
its important impact on tumorigenicity. Moreover, 
p66Shc protein level is induced by steroid hormone in the 
proliferation of several carcinoma cells and in primary 
prostate cancers [18]. The novel roles of Shc proteins, 
especially p52Shc and p66Shc, have been identified in steroid 
hormone-regulated cancers and metastasis [10]. p66Shc is 
also functionally involved in regulating oxidative stress-
induced apoptosis which mediates steroid action via the 
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redox signaling pathway [19]. Signaling activation of Shc 
is thus implicated in tumorigenesis and the behaviors of 
cancer cells, suggesting Shc’s potential as a prognosic 
marker and a target for cancer treatment.
Multiple Copies in T-cell malignancy 1 (MCT-1) 
also known as Malignant T Cell-amplified Sequence 1 
(MCTS1) was originally identified in a lymphoma cell 
line [20].  Ectopic MCT-1 expression elicits CDK4/
CDK6 kinase activity and Cyclin D1 accumulation, 
thereby stimulating cell proliferation [21]. The oncogenic 
MCT-1 enhances AKT activity and protects cells against 
programmed death under environmental stress [22].  In 
addition to be phosphorylated in vitro by CDC2 and 
involved in cell cycle progression [20, 23], MCT-1 protein 
physically interacts with the centrosomal apparatus and 
regulates mitotic progression and spindle assembly 
[24].  Overexpression of MCT-1 oncogene transforms 
NIH3T3 (murine fibroblasts) and MCF-10A (human 
breast epithelia) cells [20, 25]. Cells introducing MCT-
1 evade growth suppression and checkpoint control as 
well as proficiently promote p53 destabilization via an 
ubiquitin-proteasome pathway following DNA damage 
[26]. The synergistic promotions on the cell migration 
and tumorigenic process have been demonstrated in 
MCT-1 overexpression alongside p53 deficiency [27, 
28].  Intriguingly, induction of MCT-1 in the p53-deficient 
cells advances ERK1/2 activity [26], genomic instability 
[27], nuclear aberrations and mitotic catastrophes [24]. 
Furthermore, the posttranslational regulations associated 
with Hu Antigen R (HuR) which connects to the enhanced 
translation of tumor-promoting genes, such as Cyclin D1, 
or the decreased translation of tumor-suppressing genes, 
such as caspase 2, are altered by overexpressing MCT-
1 [29].  Relating to the HuR function and promoting of 
the angiogenicity [30, 31], the angiogenesis inhibitor 
thrombospondin-1 (TSP-1) is suppressed by the induction 
of MCT-1.
We demonstrate for the first time that both MCT-
1 and Shc genes are highly activated in human cancers. 
Targeted suppression of MCT-1 promotes caspase 
activation, apoptosis and chemo-sensitivity but inhibits 
Shc expression, anchorage-independent growth and 
xenograft tumorigenicity. 
RESULTS
High expression of MCT-1 and Shc genes in 
human cancers 
MCT-1 promotes angiogenicity and tumorigenicity 
in cancer cell xenografted mice [27, 28, 30]. The 
TissueScan Lung Cancer Tissue qPCR Array (Panel II, 
III and V) (OriGene Technologies, Inc.,) was analyzed 
the level of MCT-1 mRNA expressed in human lung 
carcinomas, in which the MCT-1 mRNA revealed a 
2-fold induction over the mean of normal lung tissue 
were recognized as high expression of MCT-1 gene. 
Accordingly, MCT-1 gene was observed to be significantly 
induced in stage I (83.3%), stage II (76.7%), stage III 
(85.3%) and stage IV (100%) of 124 lung cancer patients 
(Table 1).  Overall, 83.9% of the cancer samples showed 
a significant elevation of MCT-1 mRNA level, indicating 
the clinical relevance of MCT-1 gene stimulation in lung 
carcinomas.  Shc induction is implicated in tumorigenesis 
[6, 10, 19].  As examined in Shc mRNA level, we found 
that Shc gene was highly activated in different stages of 
lung cancer (Table 2).  Overall, 62.1% of the 124 lung 
cancer patients had a significant induction of Shc gene. 
The frequency of MCT-1 and Shc gene co-activation 
was again studied, and the results showed that 58.1% 
of the cancer patients exhibited high activation of both 
MCT-1 and Shc genes but only 11.3% of cases expressed 
low-level of both genes (Table 3).  The data of positive 
association of Shc and MCT-1 gene activation in human 
lung cancers was statistically significant (p< 0.0001).
The Breast Cancer Tissue qPCR Array (Panel III and 
IV) (OriGene Technologies, Inc.,) was further studied to 
explore the linkage of Shc and MCT-1 genes that highly 
induced in another type of human cancer.  Among 92 
breast cancer tumors, we found that 56.5% of the biopsies 
had dual activation of Shc and MCT-1 genes, but only 
14.1% of the samples had low-expression in both genes 
(Supplementary Table 1).  Highly concomitant activation 
of Shc and MCT-1 genes was also observed in human 
breast cancer (p<0.0001), revealing their clinical relevance 
on mammary tumorigenicity as well.
MCT-1 regulates the signaling cascade of Shc-
Ras-MEK-ERK 
To investigate the role of MCT-1 in Shc signaling 
pathway, the short hairpin RNA (shRNA) were transfected 
into MCF-10A, H1299 and A549 cells to knockdown 
MCT-1 gene expression (Supplementary Fig. 1A-C). 
Based on the level of MCT-1 protein production, the 
vector control transfectant was named “High” (with a 
maximal-amount of MCT-1), and the MCT-1 shRNA 
transfectants were named “Medium” (with a middle-level 
of MCT-1) and “Low” (with a low-level of MCT-1).  As 
evaluated by flow cytometry analysis in regular culture 
condition, no significant change in the cell cycle profiling 
was observed upon MCT-1 reduction (Supplementary Fig. 
1D).  
Shc participates in regulation of Ras signaling 
activation [2].  H-Ras activity was first examined to 
define whether the decrease in MCT-1 suppressed this 
essential component controlling cell proliferation (Fig. 
1A).  MCF-10A cells were starved for 24 h, followed 
by re-activation with serum for different time (5 and 15 
min).  The active H-Ras isolated by Raf-1 RBD-coupled 
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sepharose was normalized to total H-Ras levels before 
comparing with the non-silenced control cells cultured 
in a serum-free condition (time 0).  After stimulation for 
5 min, H-Ras activity showed a 5-fold increase over the 
serum-depleted control cells with a high-level of MCT-
1 (quantified as 1-fold).  However, H-Ras activity was 
less induced when the MCT-1 knockdown cells were 
stimulated by the serum for 5 min (2.6-fold) and 15 min 
(1.4-fold) (lanes 6 and 9).  Reduced H-Ras activity also 
was recognized in H1299 cells while depleting of MCT-1 
(Fig. 1B).  Consistent with inhibition of H-Ras activity, the 
phospho-activation of Raf, MEK and ERK1/2 were also 
found to be decreased upon MCT-1 reduction.  Cyclin D1, 
a proliferation marker transcriptionally regulated by ERK 
[32, 33], was again observed to be consistently reduced 
by MCT-1 knockdown.  Intriguingly, along with decrease 
in MEK-ERK signaling activation, the expression of Shc 
isoforms (p66Shc, p52 Shc, and p46 Shc) were dramatically 
suppressed corresponding to the degree of MCT-1 
knockdown in MCF-10A cells (Fig. 1C).  Similar results 
were identified in A549 cellular context that Shc proteins, 
Cyclin D1, p-ERK and p-Rb were all decreased by loss of 
MCT-1 (Fig. 1D).  Further analysis of Shc mRNA level 
indicated that knockdown of MCT-1 inhibited Shc gene 
transcription, most likely due to MCT-1’s impact on Shc 
gene transcription that accounted for the decrease of Shc 
protein (Fig. 1E and 1F). 
The direct effect of MCT-1 knockdown on cell 
propagation was evaluated by MTT assay.  After 
cultivation in regular media for 3 days, MCF-10A 
proliferation rate showed a significant difference 
comparable to the amounts of MCT-1 expression (Fig. 
1G).  MCT-1’s role in regulating A549 cell proliferation 
was next studied in regular media (Fig. 1H).  At day 9, the 
control A549 cells with a high-level of MCT-1 proliferated 
more rapidly (42-fold increase), than those of cells with a 
medium-level (29-fold increase) or with a low-level (28-
fold increase) of MCT-1 protein.  Thus, MCT-1 regulates 
cell proliferation attended with control of the Shc pathway.
Knockdown of MCT-1 enhances spontaneous cell 
death and activates caspase 3 
ERK activates MDM2 that promotes p53 
degradation [34].  We here identified that knockdown of 
MCT-1 in MCF-10A cells led to ERK dephosphorylation 
and p53 accumulation as cultured in regular media for 
5 days (Fig. 2A).  Active caspases trigger programmed 
cell death [35].  Integrin β 4 and vimentin are cleaved by 
caspase 3 and 7 in apoptosis, which have been recognized 
as potential molecular targets for cancer treatment [36-38]. 
The proteolysis of integrin β 4 (indicated by asterisks) 
and the accumulation of p53 were positively correlated 
with the decrease of MCT-1 in MCF-10A cells (Fig. 2A). 
Similarly, the levels of vimentin and p53 presentation 
were decreased by suppressing MCT-1 in A549 cells 
(Fig. 2B).  Caspase 3 activity was again analyzed by 
the cleavage of colorimetric peptide Ac-DEVD-pNA 
and the release of chromophore p-nitroaniline (pNA) 
stage MCT-1 high
MCT-1 
low Total p-value
normal 0
(0%)
19
(100%)
I 40
(83.3%)
8 
(16.7%)
48
(38.7%)
p< 0.0001
II 23 
(76.7%)
7 
(23.3%)
30 
(24.2%)
p< 0.0001
III 29 
(85.3%)
5 
(14.7%)
34 
(27.4%)
p< 0.0001
IV 12
(100%)
0
(0%)
12
(9.7%)
p< 0.0001
Total 104 
(83.9%)
20 
(16.1%)
124
(100%)
P<0.0001
Table 1. MCT-1 mRNA level in lung cancer
Table 1: MCT-1 mRNA expression levels in human 
lung cancers. The TissueScan lung cancer tissue cDNA arrays 
Panel II, III and V consisted of a total of 19 normal lung samples 
and 124 lung cancer biopsies from different individuals were 
analyzed the expression of MCT-1 mRNA by Q-RT-PCR.  The 
MCT-1 mRNA level in each tumor sample was normalized to 
β-actin mRNA and calibrated to the overall mean of MCT-1 
mRNA level of normal tissue (set as 1-fold).  MCT-1 mRNA had 
a >2-fold induction in tumor samples over normal lung tissue 
were defined as the gene high-activation.  The statistical analysis 
used Fisher’s exact test.
stage Shchigh
Shc
low Total p-value
normal 2
(12.5%)
14
(87.5%)
I/II 51
(65.4%)
27
(34.6%)
78
(62.9%)
p< 0.0001
III/IV 26
(56.5%)
20
(43.5%)
46
(37.1%)
P= 0.003
Total 77 
(62.1%)
47 
(37.9%)
124
(100%)
P=0.0002
Table 2:Shc mRNA level in lung cancer
Table 2: Shc mRNA expression levels in human lung 
cancers.  The TissueScan lung cancer tissue cDNA arrays 
(Panels II, III and V) were used to analyze the Shc gene (three 
isoforms) expression by Q-RT-PCR analysis.  The Shc mRNA 
level identified in tumors was normalized to β-actin and 
calibrated to the overall mean of Shc mRNA level of normal 
lung tissue.  Shc mRNA levels in tumors which elevated a 1.5-
fold increase over normal breast tissues were defined as the 
high-activation of Shc gene.  Shc transcripts were observed to be 
induced in lung cancers.  The statistical analysis used Fisher’s 
exact test.
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(Fig. 2C).  The quantitative data revealed more than a 
1.5-fold and a 2.5-fold increase in the relative activity 
of caspase 3 as MCT-1 differentially reduced in MCF-
10A cells (Medium and Low).  Inhibition of caspase 3 
activity was also consistently identified in A549 cells lack 
of MCT-1 (shMCT-1) (Fig. 2D).  Caspase 3 activation 
and p53 accumulation enhance apoptotic effects [39, 
40].  To exam whether intrinsic apoptosis was induced 
by targeted suppression of MCT-1, A549 cell viability 
were determined by exclusion trypan blue effect as cells 
cultured in normal media for 5 days.  The apoptotic rate 
was found to be much enhanced in knockdown of MCT-
1 (38%) even in basal, unstressed culture condition, 
comparing to high survival ability of the comparable 
control cells (7%) (Fig. 2E).  In consistence, MCF-10A cell 
viability was affected by the degree of MCT-1 reduction 
in regular culture (Supplementary Fig. 1E, indicated by 
arrowheads).  We next evaluated cell expansion ability 
at a very low cell density (1000 cells/100 mm dish) as 
described previously [41].  After incubation in regular 
media for 2 weeks (Fig. 2F), the clonogenic cell growth 
were evaluated by crystal violet staining and the results 
identified a significant decrease of clonogenic capability 
upon knockdown of MCT-1 in different cell types. 
The enhanced cleavage of integrin β4, PARP and 
pro-caspases after MCT-1 reduction
To again exam if the loss of MCT-1 promoted 
apoptosis under the starvation condition, MCF-10A cells 
were starved for the indicated time (Fig. 3A).  Being in 
the serum-free environment for 24 h, apoptotic rates were 
greatly promoted in cells with a medium-level (85%) or 
with a low-level (94%) of MCT-1 than that of control cells 
(7%).  Upon fasting for 72 h, most of the MCT-1-deficient 
cells entered apoptotic death, but only 20% of control cells 
died from such stress.  
Poly (ADP-ribose) polymerase (PARP) is cleaved 
by active caspases in apoptosis [42].  Integrin β4 (205 
kDa) is cleaved into 180- and 150-kDa products during 
apoptosis by caspase 3 and 7 [38].  During 24 h and 36 
h starvation, not only the integrin β4 but also the PARP 
were increasingly cleaved due to MCT-1 reduction (Fig. 
3B).  Since the specific proteolytic products of integrin β4 
(180 and 150 kDa) (indicated by asterisks) were steadily 
accumulated in a fasting time-dependent and in a MCT-
1 dose-dependent manner, thereby we speculated that 
the cleavage of integrin β4 relied more on the activity 
of caspases 3 and 7 in the MCT-1 knockdown cells. 
Consistent with this notion, the proteolytic activation of 
caspases 3 and 7 but not caspase 6 were detected (panels 
3-5), showing that the caspase cascade was enhanced upon 
decrease of MCT-1.
To study whether the caspase activation mediated 
apoptosis upon MCT-1 reduction (Fig. 3C), MCF-10A 
cells were cultured in the serum-free media with different 
concentrations of a general caspase inhibitor, z-VAD-
FMK (Caspase Inhibitor VI) [43].  By 24 h starvation, cell 
growth was decreased dramatically corresponding to the 
decrease of MCT-1 expression.  In treatment of z-VAD-
FMK (25 and 50 µM), the MCT-1 knockdown cells were 
protected from the apoptotic effect in a dose-dependent 
manner.  As exposed to z-VAD-FMK at concentration of 
100 µM, cell survival rates were restored even better than 
the un-stress and MCT-1-proficient state, indicating that 
the activation of caspases mediate the apoptotic effect 
collectively promoted by MCT-1 depletion and serum 
starvation.
Inhibiting cancer cell growth and chemo-
resistance by reduction of MCT-1
We next investigated whether inhibition of MCT-1 
conferred chemo-sensitivity of A549 cancer cells.  Taxol, 
a mitotic inhibitor of cancer therapy [44], was treated 
cells for 3 days and the MCT-1 knockdown cells (MCT-
1 shRNA) exhibited a higher susceptibility to Taxol that 
the apoptotic effect was much increased compared to 
the control cells (mock) (Fig. 4A).  In the response to 
topoisomerase II inhibitor [45], Doxorubicin (DOX), for 
2 days (Fig. 4B), A549 cell viability was found to be much 
reduced upon loss of MCT-1.  Consistent with increased 
cytotoxicity, the cleavage of Vimentin and PARP, and 
the proteolytically-active caspase 7 and 3 were actually 
promoted by DOX treatment, particularly in combination 
with MCT-1 knockdown (Fig. 4C).  Camptothecin (CPT), 
an inhibitor of topoisomerase I [46], its analogues are 
widely used in cancer chemotherapy [47, 48].  The MCT-
1 knockdown cells also showed to be more susceptible 
to CPT treatment for 24 h at different concentrations 
p< 0.0001 (high : low expression of  both MCT-1 and Shc
genes)
Shc
(high)
Shc
(low) 
MCT-1 
(high) 72 (58.1%) 32 (25.8%)
MCT-1
(low) 6 (4.8%) 14 (11.3%)
Table 3:Co-activation of  MCT-1 and Shc genes in lung 
cancer
Table 3: The association of MCT-1 and Shc gene 
activation in lung cancer patients (LCPs).  The co-
activation of MCT-1 and Shc genes among the 124 human 
lung cancers were studied.  Overall, 58.1% of the LCPs highly 
expressed both MCT-1 and Shc genes, but only 11.3% of the 
biopsies exhibit low expression of both genes.  The correlation 
of MCT-1 and Shc gene induction is statically significant (p< 
0.0001).  The statistical analysis used Fisher’s exact test.
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(Fig. 4D), demonstrating a much higher CPT sensitivity 
than the vector control cells (mock).  Inversely, the 
control cells showed a 20% increase in growth upon 
CPT administration (10-100 µM), and no considerable 
CPT susceptibility was noticed even upon exposure to 
200 µM of CPT.  To further exam whether the caspase 
activation involved in CPT-inhibitory effect, A549 cells 
were concomitantly treated with 100 µM CPT and 50 µM 
z-VAD-FMK for 24 h (Fig. 4E).  The results confirmed 
that the inhibition of caspase activity prevented the MCT-
1-depleted cells from cytotoxicity caused by CPT (MCT-1 
shRNA+z-VAD).  In contrast to 14% decrease in A549 cell 
viability in the absence of MCT-1, the unexpected 27% 
increase in control cell growth was identified upon CPT 
exposure for 24 h.  Overall, the growth inhibition (41%) 
exhibited as a synergistic result of CPT administration and 
MCT-1 knockdown, was effectively abolished by z-VAD-
FMK.  Thereby, targeting MCT-1 by gene silencing 
sensitizes A549 cells to be inhibited by different chemo-
agents.
Knockdown of MCT-1 attenuates A549 
tumorigenicity of xenograft mice
To study whether knockdown of MCT-1 inhibits 
malignant transformation (Fig. 5A), A549 lung cancer 
cells were performed the soft agar assay.  The results 
showed that the cells silencing MCT-1 failed to grow in a 
viscous agarose and lost anchorage-independent growth. 
The phenotypic changes are assumed to be closely related 
Figure 1: Knockdown of MCT-1 inhibits Shc-Ras-MEK-ERK signaling and cell proliferation.  (A) MCF-10A cells starved 
for 24 h were sub-cultured in regular media for different times.  GTP-bound Ras protein was isolated from cell extracts by RBD domain-
coupled sepharose.  The level of active H-Ras was normalized with β-actin amount before comparing with the active H-Ras under the serum 
starvation (set as 1-fold).  H-Ras activity is decreased by suppressing MCT-1.  (B) H-Ras activity and its downstream signaling molecules 
were also inhibited in H1299 cells with MCT-1 knockdown.  (C) Together with the reduction of Shc proteins, the accumulation of Cyclin D 
and the phosphorylation of MEK and ERK were all steadily suppressed by depleting MCT-1 in MCF-10A cells.  (D) Abolition of MCT-1 
in A549 cell also decreases the expression of Shc, p-ERK, Cyclin D1 and p-Rb than the control cells.  (E-F) As analyzed by Q-RT-PCR, 
Shc mRNA level was observed to be much reduced corresponding to the degree of MCT-1 reduction independent of cell types.  (G) MCF-
10A cells were cultured in regular media for different periods followed by MTT assay.  Significant growth attenuation was detected by 
72 h in the absence of MCT-1.  (H) A549 cells were cultured in regular media and cell proliferation rate was much reduced upon MCT-1 
knockdown.  The fold-change of each protein was quantified as compared to the vector control (set as 1-fold).
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to abort carcinogenic ability.  To investigate the effect 
of MCT-1 knockdown on tumorigenicity, the A549 cells 
with differential level of MCT-1 protein were inoculated 
subcutaneously into BALB/c nude mice.  The xenograft 
mice were maintained for 2 months, during which time 
tumor volumes were, measured every 3 or 4 days (Fig. 
5B).  The A549 cells present a high-level of MCT-1 
yielded much larger tumors, but the tumor growth was 
apparently suppressed as MCT-1 reduced to either a 
medium or to a low level (Fig. 5C).  The quantification 
data indicated that the tumor incidences decreased to 70% 
in A549 cells with a low-level of MCT-1 protein (Fig. 
5D).  The average tumor volume was also dramatically 
decreased corresponding to the extent of MCT-1 reduction 
from 508.11 mm3 in the control cells (high MCT-1) to 
153.57 mm3 (medium MCT-1) and to 88.48 mm3 (low 
MCT-1), which also referred in the tumor weights (Fig. 
5D).
As shown in immunohistochemistry, MCT-
1 protein amounts contained in the A549 tumor 
decreased progressively matching to the degree of 
MCT-1 knockdown (Fig. 5E).  Furthermore, the levels 
of p66Shc, Cyclin D1 and p-ERK in tumors were all 
comparatively reduced as MCT-1 was deficient (Fig. 5F). 
Downregulation of Shc mRNA levels in A549 tumors also 
reasonably explained the degree of Shc protein reduction 
(Fig. 5G), similar to that in the A549 cells (Fig. 1F). 
These results for the first time demonstrate the molecular 
linkage between MCT-1 expression and Shc signaling in 
tumor growth.
Loss of MCT-1 suppresses H1299 xenograft 
tumorigenicity 
The targeted-inhibition of MCT-1 was again studied 
in H1299 cells.  We found that the levels of p-ERK1/2, 
p-Rb, Shc (p66/p52) and Cyclin D proteins were 
Figure 2: Spontaneous cell death induced by silencing of MCT-1. (A) MCF-10A cells were cultured in regular media for 5 days. 
Knockdown of MCT-1 decreases p-ERK expression but enhances p53 accumulation and integrin β4 cleavages (denoted by asterisks).  (B) 
The levels of p-ERK and vimentin are reduced by suppressing MCT-1 in A549 cells as well.  The changes in total amount or in the cleaved 
products were indicated. (C) MCF-10A cell extracts were incubated with the Ac-DEVD-pNA followed by the spectrophotometric detection 
of the chromophore p-nitroaniline (p-NA).  Cells expressed a medium-level or a low-level of MCT-1 reveal higher caspase 3 activity than 
the control cells with a high-level of MCT-1.  (D) Inhibition of caspase 3 activity was observed in A549 cells with MCT-1 reduction.  (E) 
Trypan blue exclusion assay analyzed A549 cell viability upon regular cultivation for 5 days.  Spontaneous cell death (in blue) was induced 
in MCT-1 depletion.  (F) Cells were cultured at a low density (1000 cells/100 mm dish) in the respective regular media for 2 weeks. 
Clonogenic growth was detected by crystal violet staining.  Colony number and growth are decreased upon MCT-1 knockdown.  
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consistently decreased after MCT-1 depletion (Fig. 6A). 
By culturing H1299 cells in 1% FBS medium for different 
periods (Fig. 6B), the control group displayed a 5.7-fold 
increase in cell number by 72 h, whereas the cells with 
a medium-level and a low-level of MCT-1 grew much 
slowly that exhibited a 4.3-fold and a 2.7-fold increase in 
cell number, respectively.
To further investigate tumor development in the 
deficiency of MCT-1, BALB/c nude mice were inoculated 
subcutaneously (s.c.) with H1299 cancer cells (2×106) 
expressed various amounts of MCT-1 protein (High, 
Medium and Low) (Fig. 6C).  A month after injection, 
tumor burdens were observed to be greatly reduced in the 
absent of MCT-1.  At the time of sacrifice, no indication of 
tumor development from the H1299 cells with only a low-
level of MCT-1 protein.  The representative tumor images 
demonstrated a dramatic reduction of tumor loads upon 
MCT-1 inhibition.  The statistically significant differences 
were detected in tumor incidences and tumor weights 
accounting to the levels of MCT-1 expression (Fig. 6D). 
Further examining the protein presented in the tumors, 
MCT-1, Shc (p66/p52), Cyclin D1 and p-Rb showed 
particular decreases in the context of MCT-1 depletion 
(MCT-1 shRNA) compared to the control cells (mock) 
(Fig. 6E).  In agreements, MCT-1 and Shc mRNA levels 
were decreased by 40% and by 60%, coordinating with 
the status of MCT-1 reduced in tumors (Fig. 6F).  Taken 
together, the attenuation or prevention of tumor growth 
because of targeting MCT-1 again closely connects to 
the inhibitory effect on Shc-ERK-Cyclin D1 cascade. 
Upregulation of Shc activity under MCT-1 oncogenic 
stress may potentially result in promoting cancer cell 
proliferation and tumor progression.
Figure 3: Loss of MCT-1 enhances apoptotic rate under environmental stress.  (A) MCF-10A cells cultured in the serum-free 
media were evaluated by MTT analysis at the indicated time.  The MCT-1 knockdown cells (Medium and Low) exhibit low survival rates 
compared to the control cells with a high-level of MCT-1.  (B) The proteolysis of integrin β4 and PARP proteins (denoted by asterisks) are 
synergistically enhanced by MCT-1 reduction and serum depletion.  The pro-caspase 3 and 7 but not 6 are cleaved to be active, particularly 
in MCT-1 deficient condition.  Each proteolytic product or active caspase was quantified.  (C) Different concentrations of z-VAD-FMK 
were added to the serum-free media for 24 h in MCF-10A culture.  z-VAD-FMK prevents apoptosis caused by starvation and MCT-1 
deficiency in a dose-dependent manner.  
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DISCUSSION
Knockdown of MCT-1 suppresses Shc signaling 
pathway
Our current results verify that Shc isoforms are 
differentially regulated by MCT-1 which directly affects 
the signaling cascade of Shc-Ras-ERK.  The most 
significant effect occurs for the p66Shc expression examined 
so far, presumably because of the unique tumorigenic 
role of p66Shc in relation with MCT-1 oncogenic activity. 
Direct impact on Shc signaling cascade explains why 
gain-of-function MCT-1 promotes the proliferative rate 
of cells [20], and induces Cyclin D1 accumulation and 
Rb phosphorylation [21].  By supporting the xenograft 
tumorigenicity data (Fig. 5 and 6), the clinical information 
have first established the physiological relation between 
MCT-1 and Shc in human cancer development (Table 1-3 
and supplementary Table 1).
Loss-of-function MCT-1 decreases Shc protein 
levels that presumably work through either by epigenetic 
modification or by post-transcriptional modulation 
involving MCT-1 activity.  In the former case, Shc 
promoter function may be de-activated by targeting 
MCT-1, similar to inhibition of p53 gene promoter by 
overexpressing MCT-1 [28].  Shc promoter region has 
the putative Sp1 binding sites [49].  The Sp1-dependent 
gene transcription can be suppressed by the functional 
p53 [50].  MCT-1 increases Sp1 expression in the nucleus 
[25] and suppresses p53 mRNA homeostasis and p53 
protein stability [26-28].  Therefore, the p53-mediated Sp1 
reduction may be inversely elicited after MCT-1 depletion, 
by which attributes to Shc gene inhibition (Fig. 1E and 
1F).  The association of MCT-1 with ribosome may be 
another potential molecular mechanism in regulating the 
expression profiling of many signaling pathways [51], 
such as the Shc-Ras-MEK-ERK cascade.  In the other 
Figure 4: Loss of MCT-1 promotes chemo-sensitivity.  (A) A549 cells (2x104/well) were treated with Taxol (0.1 µM) for 3 days and 
highly induced apoptotic effect in the MCT-1 shRNA transfectants.  (B) Upon doxorubicin (DOX) (1 µM) treatment for 2 days, more A549 
cell death was detected in the MCT-1-silencing condition.  (C) Exposure to DOX induced more cleavage of vimentin and PARP as well 
as more active caspase 7 and caspase 3, especially in the MCT-1 knockdown cells.  (D) Different concentrations of Camptothecin (CPT) 
were administrated with A549 cells for 24 h.  MCT-1 shRNA transfection confers higher cellular sensitivity to CPT than the control cells 
(mock).  (E) A549 cells were treated with 100 µM CPT alone or together with 50 µM z-VAD-FMK (z-VAD) for 24 h.  The combination of 
CPT exposure and MCT-1 knockdown is inhibited by z-VAD that restores cell viability to the comparable control level.
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way, MCT-1’s function in promoting the efficient eIF2-
independent recruitment of aminoacylated initiator tRNA 
(Met-tRNAMETi) to initiate translation machineray may be 
also involved in modulating Shc protein translation [52].
Reduction of MCT-1 increases apoptotic event
Programmed cell death is a natural defender 
against cancer development [53], and malfunction 
of the apoptotic process can stimulate tumorigenesis 
[54].  Tumor cells have a tendency to be more resistant 
to environmental stress or chemotherapeutics partly 
due to the inactivation of pro-apoptotic signaling or 
the activation of anti-apoptotic pathway.  In addition 
to prevent genomic instability and tumor development 
[55], the accumulation of p53 transcriptionally activates 
many downstream genes which stimulate the proteolytic 
activation of caspases to trigger cell death [40].  During 
apoptosis, PARP and integrin β4 are cleaved by the active 
caspases [38, 42].  Aberrant induction of integrin β4, 
stimulates malignant tumor progression and angiogenesis 
[56, 57].  Thus, targeting integrin β4 has been predicted 
as a rational approach for cancer and anti-angiogenic 
therapies [58].  The stimulus of p53 accumulation induces 
the activation of caspase 3 and 7, through which can 
promote apoptosis and enhance degradation of integrin β4 
and PARP in targeted suppression of MCT-1 (Fig. 2 and 
3).  Accordingly, the loss-of-function MCT-1 raises the 
chemo-sensitivity of cancer cells (Fig. 4), implying that 
targeting MCT-1 may enhance the therapeutic efficacy on 
advanced and metastatic cancer.
The association of MCT-1 and Shc gene activation 
in human cancers
Shc proteins couple the receptor tyrosine kinases 
(RTKs) to Ras signaling activation through association 
Figure 5: Targeted suppression of MCT-1 attenuates A549 tumor growth.  (A) A549 cells lose transformation ability after 
MCT-1 depletion as studied with soft agar assay.  (B) A549 cells (1×106 cells/site) were injected subcutaneously into athymic nude mice 
(n=10) on both flank regions.  The tumor volumes were measured at the indicated time.  Tumor development is much reduced corresponding 
to the degree of MCT-1 knockdown.  (C) After injection for 2 months, smaller A549 tumors (enclosed in dotted circle) were emerged from 
the MCT-1 knockdown cells.  (D) The quantification results indicate decreases in the tumor incidence, volume and mass after MCT-1 
knockdown.  (E) Immunohistochemistry identified a lower MCT-1 amount (brownish) in the tumor developed from the MCT-1 knockdown 
cells.  Scale bar, 100 µm.  (F) MCT-1 reduction suppresses the expression of p66Shc, Cyclin D1 and p-ERK in the tumors.  The fold-change 
in total or each protein was indicated.  (G) Shc transcripts are significantly decreased in the tumors derived from the MCT-1-deficient cells.
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with Grb2 [59, 60].  Disrupting the interaction of Shc and 
Grb2 inhibits tumor growth of the xenograft mice [61], 
telling that Shc pathway may be served as an ideal cancer 
therapeutic target.  Consistent with the results in vitro (Fig. 
1C and 1D), significant inhibition of Shc expression in 
tumorigenic process are identified after MCT-1 depletion 
(Fig. 5 and 6), confirming that MCT-1 is a novel regulator 
of the Shc pathway.  Thereby, blockade of MCT-1 activity 
potentially inhibits not only Shc signaling cascade but 
also the oncogenicity and tumorigenicity involving 
aberrant Shc activity.  Clinical results also show important 
correlation between high-activation of both MCT-1 and 
Shc genes in different types of tumors.  Given that the 
physiological connections and the clinical relevance of 
MCT-1 and Shc expression in development of tumor, 
understanding their molecular interaction may help to 
effectively prevent cancer cell propagation and tumor 
progression.  The advanced investigation of MCT-1-
Shc pathway that tumors are dependent upon for growth 
may facilitate the identification of new and effective 
therapeutics. 
METHODS
Antibodies
Antibodies (Abs) specific for the cleaved caspase 
3 (Asp175), caspase 6, caspase 7, Cyclin D1 (92G2), 
Figure 6: Decrease of MCT-1 protein suppresses H1299 xenograft tumorigenicity. (A) The levels of Shc (p66/p52), Cyclin 
D1, p-ERK and p-Rb were found to be reduced by knockdown of MCT-1 in H1299 cells.  The quantification results indicate the degree 
of individual or total protein reduction.  (B) H1299 cells (5,000 cells/well) were cultured in the medium containing 1% FBS for different 
intervals.  Cells deficient of MCT-1 (Medium and Low) grow much slower than the control cells with a high-level of MCT-1 (High). 
(C) BALB/c nude mice were injected subcutaneously with H1299 cancer cells (2×106 cells/site) on both flank regions.  Tumor growth 
is decreased dramatically due to MCT-1 depletion.  (D) The quantification data show significant decreases of the tumor incidence and 
tumor mass derived from MCT-1-deficient cells (Medium and Low).  (E) Immunohistochemistry reveals a high-abundance of MCT-1 in 
tumor came from the control cells (mock) than developed from MCT-1 knockdown cells (MCT-1 shRNA).  Scale bar, 50 µm.  Decreased 
expression in Shc (p66/p52), Cyclin D1 and p-Rb proteins were observed in the tumor with MCT-1 knockdown.  The change in total or in 
individual protein was quantified.  (F) Q-RT-PCR study quantified MCT-1 and Shc mRNA levels being reduced in the tumors with MCT-1 
knockdown.  
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phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, phospho-
MEK1/2 (Ser217/221), MEK1/2, phospho-Rb (Ser780), 
Rb (4H1) and Shc were purchased from Cell Signaling 
Technology (Danvers, MA).  Ha-Ras (MC57) and 
vimentin (V9) Abs were obtained from Millipore 
Corporation (Billerica, MA); Abs for integrin β4 and 
PARP were purchased from BD Biosciences (Franklin 
Lakes, NJ); and Abs for p53 (DO-1) and β-actin (AC-15) 
were bought from Santa Cruz Biotechnology (Santa Cruz, 
CA) and Novus Biologicals (Littleton, CO), respectively.
Cell culture and transfection
Non-tumorigenic human mammary MCF-10A cells 
were cultured in DMEM/F-12 medium (GIBCO, Grand 
Island, NY) supplemented with 5% horse serum (HS) 
(GIBCO), 20 ng/ml EGF (ProSpec-Tany TechnoGene 
Ltd., Rehovot, Israel), 10 µg/ml insulin (Sigma, St. Louis, 
MO), 0.5 µg/ml hydrocortisone (Calbiochem, Darmstadt, 
Germany), 100 ng/ml cholera toxin (Sigma), 100 units/ml 
penicillin (GIBCO) and 100 µg/ml streptomycin (GIBCO) 
in a 5% CO2 incubator at 37oC.  Non-small cell human lung 
carcinoma cell lines, H1299 and A549, were maintained in 
RPMI 1640 medium (GIBCO) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) (GIBCO), 2 
mM/ml L-glutamine (GIBCO), 100 units/ml penicillin 
and 100 µg/ml streptomycin in a 5% CO2 incubator at 
37oC.  The pGeneClip MCTS1 shRNA (SA Biosciences 
Corp, Frederick, MD) or the control shRNA (mock) were 
transfected into cells using the jetPEI™ transfection 
reagent (Polyplus-transfection, New York, NY), followed 
by incubating with 0.5 µg/ml puromycin to select the line 
with differential reduction of MCT-1.
Western blotting assay
CytoBusterTM Protein Extraction Reagent 
(Novagen, Darmstadt, Germany) including Protease 
Inhibitor Cocktail (Sigma) and Phosphatase Inhibitor 
Cocktail 2 (Sigma) was incubated with cells at 4oC 
for 30 minutes (min).  Cell extracts were clarified by 
centrifugation at 16,000 rpm for 15 min at 4oC, and 
protein concentrations were determined by the Coomassie 
PlusTM Protein Assay Reagent (Thermo, Rockford, IL). 
The protein samples (15 µg) were mixed with TRICINE 
Sample Buffer (Protech Technology, Taipei, Taiwan) and 
heated at 95oC for 7.5 min.  The samples were resolved 
on a 4–12% Bis/Tris NuPAGE gel (Invitrogen, Carlsbad, 
CA) and then transferred to a Hybond-C Extra membrane 
(Amersham Biosciences, Piscataway, NJ) using the 
Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell 
(Bio-Red Laboratories, Hercules, CA).  The membranes 
were blocked for 1 hour (h) in PBS with 5% DifcoTM Skim 
Milk (BD Biosciences), hybridized with the indicated 
Abs and reactivated with horseradish peroxidase (HRP)-
conjugated sheep anti-mouse IgG or donkey anti-rabbit 
IgG (Amersham Biosciences) before detecting with the 
SuperSignal® West Pico Chemiluminescent Substrate 
(Thermo).  The immune-reactive signals were stripped by 
RestoreTM Western Blot Stripping Buffer (Thermo) before 
re-probing the protein of interest.
Cell proliferation and viability
Cell proliferative and survival rates were measured 
by Cell Proliferation Kit I (Roche Diagnostics Corp., 
Basel, Switzerland).  MCF-10A, H1299 and A549 cells 
were seeded in a BD FalconTM 96-well microplate (5,000 
cells per well) in triplicate and cultured in DMEM/F-12 
complete medium with 5% HS or RPMI 1640 medium 
with 10% FBS as indicated.  At the specific time, 10 µl 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT)-labeling reagent was added to each 
well for 4 h.  The formazan crystals were dissolved 
with 100 µl of Solubilization solution and incubated 
overnight at 37°C before analyzing by the Infinite M200 
Pro spectrophotometer (Tecan Group Ltd., Männedorf, 
Switzerland) at an absorbance of 595 nm.  
Cell viability was analyzed by MTT assay.  MCF-
10A cells were seeded at 1×104 cells per well and 
incubated with the serum-free DMEM/F-12 medium and 
different concentrations of Z-VAD for the indicated time. 
To test cellular sensitivity to chemotherapeutic agents, 
A549 cells were cultured at 2×104 cells per well with 10% 
FCS containing RPMI 1640 medium and treated with 0.1 
µM Taxol (Sigma), 1 µM Doxorubicin (DOX) (Sigma), or 
different concentrations of Camptothecin (CPT) (Sigma) 
for the indicated time.
Cell cycle profiling and programmed cell death 
To analyze the cell cycle distribution, cells were 
harvested by 0.25% trypsin/1 mM EDTA, washed with 
PBS, fixed in 70% ethanol and stored at -20oC.  The cells 
were washed twice with ice-cold PBS and incubated 
with 10 µg/ml propidium iodide (PI) (Sigma) and 10 
µg/ml RNase A in PBS (Sigma) at 4oC overnight.  All 
the suspension and adhesion cells were collected, 
washed twice with PBS and stained with Annexin V 
apoptosis detection kit (BD Bioscience) for 15 min 
at room temperature.  The Annexin V-positive cells 
were analyzed by the BD FACSCalibur flow cytometer 
(Becton-Dickinson, San Jose, CA).  Both PI and Annexin 
V-FITC were excited at 488 nm, and the emissions were 
determined by FL2 PMT (564-606 nm bandpass filter) and 
FL1 PMT (515-545 nm bandpass filter).  The results were 
analyzed using the Windows Multiple Document Interface 
(WinMDI), version 2.8 software developed by Scripps 
Research Institute (La Jolla, CA).
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Caspase 3 activity 
Caspase 3 Colorimetric Activity Assay Kit 
(Millipore Corporation) was used to measure activity of 
caspase 3 by conversion of a colorimetric substrate, Ac-
DEVD-pNA.  The cells were cultured for 5 days and 
harvested by the Cell Lysis Buffer.  The protein samples 
(100 µg) were incubated with 5X Assay Buffer, 10 µl 
Ac-DEVD-pNA and ddH2O in a total volume of 100 µl 
at 37oC for 2 h.  The spectrophotometric detection of the 
chromophore p-nitroaniline (p-NA) was analyzed by the 
Infinite® M200 Pro spectrophotometer at an absorbance 
of 405 nm.
Ras activity assay
Cells were starved in the serum-free media for 24 h 
before serum activation for the indicated time.  The active 
Ras was isolated by the agarose-coupled Ras-binding 
domain (RBD) of Raf-1 using the Ras Assay Reagent 
(Millipore Corporation).  The cells were extracted in 
Magnesium-containing Lysis Buffer (MLB), 500 µg 
protein samples were incubated with 10 µg Raf-1 RBD-
coupled agarose in a total volume of 500 µl and then 
gently rotated at 4oC for 1 h.  Raf-1 RBD-coupled beads 
were collected by quick centrifugation at 14,000 g at 4oC 
and washed 3 times with ice-cold MLB.  The active Ras 
bound to the Raf-1 RBD beads were resolved by SDS-
PAGE and detected by H-Ras Ab.
Trypan blue exclusion, clonogenic growth and 
anchorage-independent growth assays
Cells were cultured for 1 and 5 days in regular media 
and then stained with 0.4% trypan blue in PBS for 10 
min.  Trypan blue-positive cells indicating the dead cells 
without intact membrane were observed under a Nikon 
ECLIPSE TS100 inverted microscope and photographed 
by a Canon EOS 50D camera.
Cells were cultured at a low density (1000 cells/100 
mm dish) in regular media for 2 weeks, the surviving 
clonogenic cells were washed by PBS, fixed with 50% 
and 100% methanol for 10 min each before staining 
with 0.05% crystal violet in 2% ethanol for 30 min.  The 
clonogenic cells were photographed by a Canon Digital 
IXUS 850 IS camera. 
A549 cells were performed soft agar assay to 
analyze the effect of anchorage-independent growth upon 
MCT-1 knockdown as described [25].  
Quantitative real-time polymerase chain reaction 
(Q-RT-PCR)
Total cellular RNA was isolated by TRIzol reagent 
(Invitrogen).  The quality and quantity of RNA were 
determined by the NanoDrop ND-1000 Spectrophotometer 
(Thermo).  Total RNA was reversely-transcribed into 
complementary DNA (cDNA) using the QuantiTect 
Reverse Transcription Kit (QIAGEN, Hilden, Germany). 
The specific probes (FAM dye-labeled MGB quencher) 
for MCT-1 (assay ID: Hs00273873_m1), Shc (assay ID: 
Hs01050691_g1) and beta-actin (assay ID: Hs99999903_
m1) were purchased from Applied Biosystems (Forster 
City, CA).  Q-RT-PCR was performed in triplicate in a 10 
µl mixture, containing 4 ng cDNA, 0.5 µl TaqMan probe, 
5 µl TaqMan PCR Master Mix (Applied Biosystems) and 
2.5 µl deionized water (DNase-free and RNase-free). 
By use of ABI Prism 7900 Fast Real-Time PCR system 
(Applied Biosystems), PCR reactions were conducted 
as follows: 95oC for 10 min, 45 cycles of denaturing at 
95oC for 15 seconds and annealing at 60oC for 1 min. 
The mRNA level of the target gene was normalized to 
β-actin mRNA level and calculated by the formula: Cycle 
threshold (ΔCT) = Ct target gene – Ct internal control.  The 
relative mRNA level of each gene was determined by the 
formula: ΔΔCT =ΔCT control group – Ct experimental 
group.  The fold change was calculated by the formula: 
2-ΔΔCT.
Tumorigenicity of cancer cell xenograft mice
To assess the tumorigenic effect upon MCT-1 
knockdown, H1299 (2×106) and A549 (1×106) lung 
cancer cells were injected subcutaneously (s.c.) into the 
flank region at both sites of 6 week-old female BALB/c 
nude mice (BALB/cAnN-Foxnlnu/CrlNarl).  All animal 
studies were conducted in accordance with the Animal 
Use Protocol approved by the National Health Research 
Institutes (NHRI-IACUC-098074-A).  The tumor 
development was monitored every 3 or 4 days, and 
calculated by the formula: volume= 1/2 × L × W2, where 
L is the length and W is the width.  
Immunohistochemistry study
The tumor tissues were fixed in 10% formalin and 
embedded in paraffin.  The 4 µm thick paraffin-embedded 
tissue sections were deparaffinized twice in xylene 
for 10 min and twice in ethanol for 2 min.  The tumor 
sections were placed in 100 mM Tris-HCl (pH 6.0), 50 
mM ethylenediaminetetraacetic acid (EDTA), heated at 
92oC for 15 min and washed 3 times with PBS.  After the 
endogenous peroxidase activity being blocked by 30% 
H2O2 for 5 min, samples were stained by the indicated 
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Ab for 2 h, washed 3 times with PBS, incubated with 
LSAB2 kit/HRP System (DakoCytomation Denmark A/S, 
Glostrup, Denmark) and counterstained with hematoxylin. 
Images were observed by a Nikon Optiphot-2 Upright 
Microscope (Nikon Corporation, Tokyo, Japan) with a 
20X objective lens, photographed by a Nikon DXM1200 
CCD digital camera and analyzed by the Nikon ACT-1 
imaging capture software under the same profile.
MCT-1 and Shc mRNA expression levels in 
human cancers
The normalized cDNA samples of the TissueScan 
Lung Cancer Tissue qPCR Panel II, III and V (OriGene 
Technologies, Inc., Rockville, MD) were assayed the 
levels of MCT-1 and Shc gene activation in normal vs. 
cancerous lung tissues.  The normalized cDNA samples 
from the TissueScan Breast Cancer Tissue qPCR Panel 
III and IV (OriGene Technologies, Inc.) were analyzed 
MCT-1 and Shc gene activation in normal vs. breast 
cancer tissues. The comprehensive pathology information 
for each sample is provided on the OriGene web site.  The 
relative mRNA level of each target gene was analyzed by 
Q-RT-PCR and calculated by the formula: ΔCT =Ct normal 
tissue group – Ct cancer group. The fold difference was 
calculated by the formula: 2-ΔCT.
Statistics
The statistical analyses were assessed by Student’s 
t test to compare the mean of control and experimental 
groups. The comparison between cancer and normal 
samples and the co-activation MCT-1 and Shc genes in 
human cancers were analyzed by Fisher’s exact test (In-
Silico Online; http://in-silico.net/). A p value＜0.05 is 
considered to be statistically significant.  
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